HC Wainwright Has Pessimistic Outlook of ANIP Q3 Earnings

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) – Equities researchers at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for ANI Pharmaceuticals in a note issued to investors on Tuesday, August 11th. HC Wainwright analyst B. Folkes now forecasts that the specialty pharmaceutical company will earn $1.66 per share for the quarter, down from their prior estimate of $1.94. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $8.03 per share. HC Wainwright also issued estimates for ANI Pharmaceuticals’ Q4 2026 earnings at $2.58 EPS and FY2026 earnings at $7.78 EPS.

A number of other equities analysts have also recently weighed in on ANIP. Canaccord Genuity Group lowered their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Guggenheim lowered their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Finally, Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $105.83.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $76.87 on Wednesday. ANI Pharmaceuticals has a 52 week low of $70.15 and a 52 week high of $99.50. The stock’s fifty day moving average is $80.65 and its two-hundred day moving average is $78.97. The company has a market capitalization of $1.77 billion, a P/E ratio of 16.57 and a beta of 0.44. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping the consensus estimate of $2.04 by $0.17. The company had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same period in the prior year, the business posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS.

Institutional Trading of ANI Pharmaceuticals

Large investors have recently modified their holdings of the stock. KBC Group NV purchased a new position in ANI Pharmaceuticals in the first quarter valued at $28,000. Advisors Asset Management Inc. purchased a new stake in ANI Pharmaceuticals during the 1st quarter worth about $28,000. Hantz Financial Services Inc. raised its position in ANI Pharmaceuticals by 70.3% in the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $48,000. Finally, State of Wyoming purchased a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 3,162 shares of ANI Pharmaceuticals stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $77.00, for a total value of $243,474.00. Following the completion of the transaction, the senior vice president directly owned 75,534 shares of the company’s stock, valued at $5,816,118. The trade was a 4.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Meredith Cook sold 500 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the sale, the vice president directly owned 74,424 shares in the company, valued at approximately $5,617,523.52. The trade was a 0.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 18,987 shares of company stock valued at $1,546,405. Corporate insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.